DDInter790 DDInter1828
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Furosemide {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Furosemide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Furosemide {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Furosemide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Furosemide {u} (Compound) resembles {v} (Compound) Bumetanide
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Furosemide {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Furosemide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Furosemide {u} (Compound) treats {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Niacin
Niacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Furosemide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Tolbutamide (Compound)
Furosemide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Furosemide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Furosemide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Furosemide (Compound) resembles Bumetanide (Compound) and Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Furosemide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Chlorpropamide (Compound) and Chlorpropamide (Compound) resembles Tolbutamide (Compound)
Furosemide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)
Furosemide (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Niacin (Compound) and Niacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide